Overview

Alemtuzumab + Rituximab Consolidation in CLL

Status:
Terminated

Trial end date:
2010-12-01

Target enrollment:

Participant gender:

Summary

The goal of this clinical research study is to find out how well Campath (alemtuzumab), Rituxan (rituximab), or a combination of the 2 drugs may control Chronic Lymphocytic Leukemia (CLL) that is left after chemotherapy. The safety of these drugs will also be studied.

Phase:

Phase 2

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborator:

Genzyme, a Sanofi Company

Treatments:

Alemtuzumab
Rituximab